GeneralNeutralBlockonomi · 3h ago5/10
📰
Nurix Therapeutics (NRIX) Stock Drops as Roche Announces $2.3 Billion Cancer Drug Partnership
Nurix Therapeutics announced a $2.3 billion partnership with Roche for the blood cancer drug bexobrutinib, with $700 million upfront and Phase III trials launching this summer. Despite the significant partnership value, NRIX stock declined following the announcement, suggesting market concerns about deal terms or valuation metrics.